Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

MIB · Multi-modal, Endoscopic Biophotonic Imaging of Bladder Cancer for Point-of-Care Diagnosis

H2020Status: CLOSED1 January 201631 December 2021EU funding €5,983,808Call H2020-PHC-2014-2015

Bladder cancer is among the most expensive diseases in oncology in terms of treatment costs; each procedure requires days of hospitalisation and recurrence rates are high. Current unmet clinical needs can be addressed by optical methods due to the combination of non-invasive and real-time capture of unprecedented biomedical information.The MIB objective is to provide robust, easy-to-use, cost-effective optical methods with superior sensitivity and specificity to enable a step-change in point-of-care diagnostics of bladder cancer. The concept relies on combining optical methods (optical coherence tomography, multi-spectral opto-acoustic tomography, shifted excitation Raman difference spectroscopy, and multiphoton microscopy) providing structural, biochemical and functional information. The hypothesis is that such combination enables in situ diagnosis of bladder cancer with superior sensitivity and specificity due to unprecedented combined anatomic, biochemical and molecular tissue information. The step-change is that this hybrid concept is provided endoscopically for in vivo clinical use.The project relies on development of new light sources, high-speed imaging systems, unique imaging fibre bundles, and endoscopes, combined and applied clinically. The consortium comprises world-leading academic organisations in a strong partnership with innovative SMEs and clinical end-users. Through commercialization of this novel imaging platform, MIB is expected to reinforce leading market positions in medical devices and healthcare for the SMEs in areas where European industry is already strong. The impact is that improved diagnostic procedures facilitate earlier onset of effective treatment, thus recurrence and follow-up procedures would be reduced by 10%, i.e., reducing costs. Using MIB technology, healthcare cost savings in the order of 360M€ are expected for the whole EU. Equally important, prognosis and patient quality of life would improve drastically.

Consortium · 12 organisations

coordinator

DANMARKS TEKNISKE UNIVERSITET

DK · €829,255

participant

GRINTECH GMBH

DE · €365,475

participant

MEDIZINISCHE UNIVERSITAET WIEN

AT · €689,078

participant

LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.

DE · €653,875

participant

REGION HOVEDSTADEN

DK · €479,081

participant

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

DE · €655,046

participant

FORSCHUNGSVERBUND BERLIN EV

DE · €643,064

participant

M-SQUARED LASERS LIMITED

UK · €512,500

participant

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

DE · €195,000

participant

2M ENGINEERING LIMITED

UK · €502,103

participant

Blazejewski MEDI-TECH GMBH

DE · €432,813

participant

FERDINAND-BRAUN-INSTITUT GGMBH LEIBNIZ- INSTITUT FUR HOCHSTFREQUENZTECHNIK

DE · €26,518

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.